TRPV1 and drug-induced dyskinesia: The most probable explanation for these effects came from a study where it was observed that TRPV1 blockade positively regulates the crosstalk between endocannabinoid receptors and TRPV1 downstream signaling which helps prevent L-DOPA induced dyskinesias (Lee et al., 2006; Giuffrida and Morgese, 2007; Morgese et al., 2007; Dos-Santos-Pereira et al., 2016).